Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212561 | 1.00 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157395 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL30212596 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL15231700 | 0.81 | CREBBP (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157211 | 0.81 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157277 | 0.80 | MGAT2 (0.34) | CREBBPBRD4 | |
| SCHEMBL31049730 | 0.80 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL25377725 | 0.80 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24156604 | 0.80 | GAA (0.38) | MEN1KMT2A | |
| SCHEMBL30212563 | 0.80 | MGAT2 (0.34) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2021260092-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | ASTRAZENECA AB (SE) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795158-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | BRPF1 2632/4885CREBBP 1032/4885GSK3B 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.